India's Generic Copies Reshape Obesity Drug Market. Generic versions of semaglutide have rapidly gained traction in India's GLP-1 segment, capturing 33% market share within weeks of launch compared to 25% previously. This surge comes directly at Eli Lilly's expense, with its tirzepatide-based Mounjaro declining from 71% to 64% market share. Mounjaro sales dropped to 1.14 billion rupees in March from 1.35 billion rupees the prior month. India represents the first major test case for how quickly generics erode branded drug dominance as semaglutide's patents expire globally. Torrent Pharmaceuticals has emerged as the leading generic competitor with 8% market share, while Novo Nordisk retains 70%. Analysts describe the current phase as a gold rush as patent cliffs approach in major emerging markets worldwide, signaling significant competitive pressure ahead for both companies.
Post from MarketNews_en
Log in to interact with content.